肿瘤预防与治疗2019，Vol.32Issue(9)：807-815,9.DOI:10.3969/j.issn.1674-0904.2019.09.009
错配修复缺陷对贝伐珠单抗治疗转移性结直肠癌的预后影响*
Effect of Defective Mismatch Repair Status on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Therapy
摘要
Abstract
Objective: This study aims to identify effect of defective mismatch repair (MMR) status on prognosis of pa-tients with metastatic colorectal cancer treated with bevacizumab. Methods: Clinicopathological features and follow-up infor-mation of patients with mCRC treated with bevacizumab combined with chemotherapy ( Bev-group) or chemotherapy only (Chemo-group) in the Sixth Affiliated Hospital of Sun Yat-sen University from February 2012 to February 2015 were retro-spectively analyzed. The relationship between overall survival (OS) and clinicopathological features was studied by using Ka-plan-Meier survival curve. The prognostic factors of patients with mCRC treated by bevacizumab was evaluated by multivari-ate COX model. Results: A cohort of 163 patients (95 in Bev-group and 68 in Chemo-group) were enrolled in this study. Out of 123 patients evaluated for MMR, 13 patients showed MMR-deficient (dMMR). In Bev-group, median OS was 41. 0 months and 24. 9 months for patients with dMMR and MMR-proficient (HR=0. 12, 95% CI: 0. 017~0. 89, P=0. 001) re-spectively, while in Chemo-group the median OS was 8. 8 months and 19. 7 months (HR=11. 26, 95% CI: 2. 7~48. 0, P<0. 001) respectively. Multivariate COX model included age, carcinoembryonic antigen, KRAS gene, MMR status and grouping strategy. MMR status * grouping strategy interactive variable was an independent influencing factor of OS in pa-tients with advanced colorectal cancer in this cohort (Pinteraction=0. 037). Conclusion: Patients with dMMR treated with bevacizumab plus chemotherapy enjoyed better OS than those treated with chemotherapy alone.关键词
贝伐珠单抗/转移性结直肠癌/总生存时间/错配修复Key words
Bevacizumab/Metastatic colorectal cancer/Overall survival/Mismatch repair分类
医药卫生引用本文复制引用
凌家瑜,李唯伟,张剑威,蔡月,胡华斌,黄美近,康亮,任东林,邓艳红..错配修复缺陷对贝伐珠单抗治疗转移性结直肠癌的预后影响*[J].肿瘤预防与治疗,2019,32(9):807-815,9.基金项目
广州市科技计划(编号:201803010073) This study was supported by Guangzhou Science and Technology Plan( NO. 201803010073). （编号:201803010073）
